Reuters sources are reporting that Merck is considering selling a large portfolio of off-patent drugs with a potential $15B pricetag.
Merck is working with an investment bank on the off-patent assets sale, which may attract interest from generic drugmakers, Reuters reports.
This news comes as Merck nears the potential sale of its $14B consumer healthcare business.
Merck's asset disposal efforts are in line with recent moves by drugmakers to sell off non-core divisions in order to better focus on core products.
Read the Reuters press release